HNRNPA2B1 and breast cancer: Moreover, in the same study, the overexpression of HNRNPA2/B1 resulted in reduced MCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine resistance in BC cells.